Bevacizumab in the treatment of high-grade gliomas: an overview
- 21 August 2011
- journal article
- review article
- Published by Springer Nature in Angiogenesis
- Vol. 14 (4) , 423-430
Abstract
Angiogenesis is a process that is integral to the pathogenesis of high-grade gliomas. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor has emerged as an important therapeutic agent. Data from clinical trials in both recurrent and newly-diagnosed gliomas have shown improved radiological responses and quality of life with acceptable morbidity. However, an improvement in overall survival has not yet been seen and there are concerns on possible change in the pattern of relapse following therapy. Several unanswered questions remain including the dose, timing and sequencing that warrant further research.Keywords
This publication has 40 references indexed in Scilit:
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and miceNeuro-Oncology, 2010
- Central Nervous System Tumors2010
- Combining Bevacizumab with Temozolomide Increases the Antitumor Efficacy of Temozolomide in a Human Glioblastoma Orthotopic Xenograft ModelNeoplasia, 2008
- VEGF-A splicing: the key to anti-angiogenic therapeutics?Nature Reviews Cancer, 2008
- Vascular Endothelial Growth Factor (VEGF)-A165b Is a Weak In vitro Agonist for VEGF Receptor-2 Due to Lack of Coreceptor Binding and Deficient Regulation of Kinase ActivityCancer Research, 2008
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.Journal of Neuro-Oncology, 2001
- Glioblastoma Cells Do Not Intravasate into Blood VesselsNeurosurgery, 1995
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993